For more than a decade, I have been thinking about writing this book.
The idea began long before ALS became a public discussion point for me. It started when I first arrived at what was, at the time, a highly unconventional conclusion: that the dynamics of stress granules might be central to my own sporadic TDP-43 ALS.
Over the years, more and more pieces have fallen into place.
What began as a narrow hypothesis about one molecular mechanism gradually evolved into something broader - an energy balance hypothesis that may connect many apparently different forms of ALS under the same fundamental principle.
In short, I believe ALS is, at its core, starvation of the most energy-challenged cells in the human body.
That is why the disease appears to selectively target motor neurons. These cells operate extraordinarily close to their energetic limits even under normal conditions. They are large, metabolically expensive, constantly active, and uniquely dependent on maintaining long axons, ion gradients, intracellular transport, protein quality control, and synaptic function simultaneously over an entire lifetime.
The margin is razor-thin.
Different ALS variants appear to damage different parts of this balance. Some impair mitochondrial function. Some increase the energy cost of protein handling and autophagy. Some disrupt transport systems inside the neuron. Some alter RNA processing, stress granule behavior, or membrane excitability. Some increase the inflammatory burden. Others may reduce the efficiency of energy production itself.
But despite their differences, many of these pathways converge toward the same endpoint:
The neuron spends more energy than it can sustainably produce.
The exact route differs between genotypes, mutations, and sporadic disease forms, but the direction is strikingly similar. Each variant worsens the energy equation in its own way.
That may also explain why variant-indifferent ALS drug trials fail so consistently.
If ALS is not a single disease but many different mechanisms that collapse the same fragile energy balance, then treating all patients as a single, uniform population is almost guaranteed to dilute meaningful effects into statistical noise. A therapy helping one subtype may do little - or even cause harm - in another.
Frankly, the balance appears so delicate that it is almost a miracle we do not all get ALS.
Motor neurons survive for decades while operating under enormous energetic stress, continuously maintaining structures of extreme size and complexity without replacement. The system’s resilience is extraordinary. But once the balance shifts too far - whether through genetics, aging, cumulative stress, metabolism, inflammation, or environmental factors - the system may no longer have enough margin left to compensate.
This book is not written from the perspective of a neurologist. I am an engineer who found himself confronting this disease against his own will. And now I’m about to focus on that one question:
What if ALS is fundamentally a problem of energy economics inside the most demanding cells in the human body?